Anika Therapeutics Inc. (NASDAQ:ANIK) insider Richard Hague sold 5,250 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $54.48, for a total value of $286,020.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Anika Therapeutics Inc. (ANIK) traded down $0.38 on Friday, reaching $54.74. The company’s stock had a trading volume of 51,309 shares, compared to its average volume of 99,329. The firm has a market capitalization of $803.17, a P/E ratio of 25.72, a price-to-earnings-growth ratio of 2.88 and a beta of 1.47. Anika Therapeutics Inc. has a 12-month low of $41.64 and a 12-month high of $60.29.

Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.05. The firm had revenue of $27.18 million during the quarter, compared to the consensus estimate of $27.44 million. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 earnings per share. analysts forecast that Anika Therapeutics Inc. will post 1.9 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in shares of Anika Therapeutics during the 3rd quarter valued at $118,000. State of Alaska Department of Revenue lifted its position in shares of Anika Therapeutics by 79.5% during the 2nd quarter. State of Alaska Department of Revenue now owns 2,872 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 1,272 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its position in shares of Anika Therapeutics by 3.0% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,450 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 100 shares during the last quarter. Stevens Capital Management LP acquired a new stake in shares of Anika Therapeutics during the 3rd quarter valued at $222,000. Finally, Victory Capital Management Inc. lifted its position in shares of Anika Therapeutics by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,060 shares of the biotechnology company’s stock valued at $200,000 after acquiring an additional 608 shares during the last quarter. Hedge funds and other institutional investors own 84.86% of the company’s stock.

A number of equities research analysts have weighed in on ANIK shares. BidaskClub upgraded Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 8th. Barrington Research upped their target price on Anika Therapeutics from $53.00 to $57.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th.

WARNING: “Anika Therapeutics Inc. (ANIK) Insider Richard Hague Sells 5,250 Shares” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/01/anika-therapeutics-inc-anik-insider-richard-hague-sells-5250-shares.html.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Insider Buying and Selling by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Stock Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related stocks with our FREE daily email newsletter.